Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema

被引：27

作者：

Hwang, Jacqueline R. ^{[1
]}

Hwang, Gloria ^{[2
]}

Johri, Ansh ^{[2
]}

Craig, Timothy ^{[3
]}

机构：

[1] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[2] Penn State Univ, Coll Med, Hershey, PA 17033 USA

[3] Penn State Univ, Coll Med Allergy Asthma & Immunol, Dept Med & Pediat, Hershey, PA 17033 USA

来源：

IMMUNOTHERAPY | 2019年 / 11卷 / 17期

关键词：

BCX7353; bradykinin; hereditary angioedema; kallikrein; prophylaxis; small molecule; therapy; THERAPY;

D O I：

10.2217/imt-2019-0128

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hereditary angioedema (HAE) is rare disorder caused by a SERPING1 gene mutation that triggers severe swelling of the skin and upper airway. Treatment options for HAE with deficient and dysfunctional C1-inhibitor are expanding to include small-molecule drugs that inhibit protein interactions in the kallikrein-kinin system. Discovered by BioCryst Pharmaceuticals, BCX7353 is a synthetic, once-daily, small molecule drug that can be taken as an oral capsule to treat HAE attacks and for prophylaxis. This article will summarize recent and current BCX7353 clinical trials. Overall, results indicate BCX7353 is a promising form of therapy with a rapid 1 h onset of action, long duration of action, and acceptable tolerance.

引用

页码：1439 / 1444

页数：6

共 50 条

[1] Preclinical Characterization of BCX7353, an Oral Plasma Kallikrein Inhibitor, for the Treatment of Hereditary Angioedema (HAE)
Chen, Xilin
Kotian, Pravin
Wilson, Ramanda
Parker, Cynthia D.
Babu, Y. S.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB230 - AB230
[2] Final results from the ZENITH-1 study: Oral administration of plasma kallikrein inhibitor BCX7353 for the treatment of attacks in patients with hereditary angioedema
Longhurst, H. J.
Stobiecki, M.
Zanichelli, A.
Huissoon, A.
Moldovan, D.
Maurer, M.
Magerl, M.
Cancian, M.
Senter, R.
Manson, A.
Aygoeren-Puersuen, E.
Grivcheva-Panovska, V
Hagin, D.
Steiner, U.
Kiani-Alikhan, S.
Agmon-Levin, N.
Bygum, A.
Aberer, W.
Faust, S. N.
Launay, D.
Gompels, M.
Triggiani, M.
Bethune, C.
Reshef, A.
Cornpropst, M.
Dobo, S.
Van Dyke, S.
Murray, S.
Collis, P.
Sheridan, W. P.
Farkas, H.
Cicardi, M.
[J]. ALLERGY, 2019, 74 : 10 - 11
[3] PHARMACOKINETICS AND PHARMACODYNAMICS OF BCX7353, AN ORAL PLASMA KALLIKREIN INHIBITOR, IN HEALTHY JAPANESE SUBJECTS
Cornpropst, M.
Dobo, S.
Collis, P.
Collier, J.
Sheridan, W.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S33 - S33
[4] Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial
Longhurst, Hilary
Moldovan, Dumitru
Bygum, Anette
Cicardi, Marco
Huissoon, Aarnoud
Aygoren-Pursun, Emel
Grivcheva-Panovska, Vesna
Hagin, David
Steiner, Urs
Stobiecki, Marcin
Aberer, Werner
Bethune, Claire
Faust, Saul N.
Kiani, Sorena
Launay, David
Maurer, Marcus
Rae, William
Reshef, Avner
Cornpropst, Melanie T.
Dobo, Sylvia M.
VanDyke, Sharon
Murray, Sharon
Collis, Phillip J.
Sheridan, William P.
Farkas, Henriette
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB37 - AB37
[5] Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)
Kotian, Pravin L.
Wu, Minwan
Vadlakonda, Satish
Chintareddy, Venkat
Lu, Pengcheng
Juarez, Luis
Kellogg-Yelder, Debra
Chen, Xilin
Muppa, Saritha
Chambers-Wilson, Ramanda
Parker, Cynthia Davis
Williams, Jason
Polach, Kevin J.
Zhang, Weihe
Raman, Krishnan
Babu, Yarlagadda S.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (17) : 12453 - 12468
[6] Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies
Manning, Michael E.
Kashkin, Jay M.
[J]. ALLERGY AND ASTHMA PROCEEDINGS, 2021, 42 (04) : 274 - 282
[7] ORAL ADMINISTRATION OF A LIQUID FORMULATION OF BCX7353 RAPIDLY PROVIDES SUSTAINED CONCENTRATIONS AND KALLIKREIN INHIBITION
Mathis, A.
DeSpirito, M.
Cornpropst, M.
Sheridan, W.
Aygoeren-Puersuen, E.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S32 - S32
[8] BCX7353, a once-daily oral kallikrein inhibitor, is effective and safe in the prophylaxis of acute attacks in patients with hereditary angioedema: Attack-level analysis of the APeX-1 study
Aygoeren, E.
Bygum, A.
Steiner, U.
Magerl, M.
Panovska, Grivcheva, V
Farkas, H.
Huissoon, A.
Graff, J.
Lleonart, R.
Rae, W.
Aberer, W.
Longhurst, H.
Smith, W.
Zanichelli, A.
Cancian, M.
Guilarte, M.
Triggiani, M.
Gompels, M.
Fang, L.
Cornpropst, M.
Clemons, D.
Collis, P.
Dobo, S.
Sheridan, W. P.
Maurer, M.
Cicardi, M.
[J]. ALLERGY, 2017, 72 : 584 - 585
[9] BCX7353: AN EFFECTIVE AND SAFE ORAL PROPHYLAXIS AGAINST ATTACKS OF HEREDITARY ANGIOEDEMA. APEX-1 FINAL RESULTS
Aygoeren-Puersuen, E.
Bygum, A.
Panovska, V. Grivcheva
Steiner, U.
Huissoon, A.
Kinaciyan, T.
Fain, O.
Longhurst, H.
Farkas, H.
Fang, L.
Cornpropst, M.
Clemons, D.
Dobo, S.
Maurer, M.
Cicardi, M.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : E4 - E4
[10] Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
Aygoeren-Puersuen, E.
Bygum, A.
Grivcheva-Panovska, V.
Magerl, M.
Graff, J.
Steiner, U. C.
Fain, O.
Huissoon, A.
Kinaciyan, T.
Farkas, H.
Lleonart, R.
Longhurst, H. J.
Rae, W.
Triggiani, M.
Aberer, W.
Cancian, M.
Zanichelli, A.
Smith, W. B.
Baeza, M. L.
Du-Thanh, A.
Gompels, M.
Gonzalez-Quevedo, T.
Greve, J.
Guilarte, M.
Katelaris, C.
Dobo, S.
Cornpropst, M.
Clemons, D.
Fang, L.
Collis, P.
Sheridan, W.
Maurer, M.
Cicardi, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04): : 352 - 362

← 1 2 3 4 5 →